On the public citation graph

Targeting the HGF/Met signalling pathway in cancer

https://doi.org/10.1016/j.ejca.2010.02.028

0 signed · 296 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/(sici)1097-0142(20000415)88:8<1801::aid-cncr7>3.3.co;2-lopenalex-snapshot

Frequency of TPRMET rearrangement in patients with gastric carcinoma and in first‐degree relatives

inferredcites →https://doi.org/10.1002/ijc.20598openalex-snapshot

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

inferredcites →https://doi.org/10.1002/j.1460-2075.1992.tb05315.xopenalex-snapshot

Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.

inferredcites →https://doi.org/10.1002/jcb.10358openalex-snapshot

HGF/SF‐met signaling in the control of branching morphogenesis and invasion

inferredcites →https://doi.org/10.1002/prot.1069openalex-snapshot

Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies

inferredcites →https://doi.org/10.1016/0014-5793(92)81356-qopenalex-snapshot

Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity

inferredcites →https://doi.org/10.1016/0270-9139(91)90068-7openalex-snapshot

Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804

inferredcites →https://doi.org/10.1016/j.bbrc.2005.05.131openalex-snapshot

Mechanisms and significance of bifunctional NK4 in cancer treatment

inferredcites →https://doi.org/10.1016/j.ccr.2004.05.032openalex-snapshot

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

inferredcites →https://doi.org/10.1016/j.ccr.2004.06.013openalex-snapshot

The Sema domain of Met is necessary for receptor dimerization and activation

inferredcites →https://doi.org/10.1016/j.ijrobp.2007.07.183openalex-snapshot

Sensitization of a Glioblastoma Multiforme (GBM) Cell Line by MP470: A Novel c-Met Antagonist

inferredcites →https://doi.org/10.1016/j.molmed.2005.04.005openalex-snapshot

Cancer therapy: can the challenge be MET?

inferredcites →https://doi.org/10.1016/j.sbi.2005.09.002openalex-snapshot

A protein canyon in the FGF–FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs

inferredcites →https://doi.org/10.1016/j.uct.2009.01.001openalex-snapshot

The MET axis as a therapeutic target

inferredcites →https://doi.org/10.1016/s0014-5793(01)03126-xopenalex-snapshot

Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo

inferredcites →https://doi.org/10.1016/s0021-9258(19)88673-8openalex-snapshot

Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer.

inferredcites →https://doi.org/10.1016/s0960-9822(98)70059-4openalex-snapshot

Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo

inferredcites →https://doi.org/10.1016/s0962-8924(03)00104-1openalex-snapshot

How to make tubes: signaling by the Met receptor tyrosine kinase

inferredcites →https://doi.org/10.1016/s1535-6108(03)00085-0openalex-snapshot

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

inferredcites →https://doi.org/10.1021/bi900438wopenalex-snapshot

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

inferredcites →https://doi.org/10.1021/jm801586sopenalex-snapshot

Discovery of N -(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

inferredcites →https://doi.org/10.1023/a:1023768811842openalex-snapshot

c-Met: Structure, functions and potential for therapeutic inhibition

inferredcites →https://doi.org/10.1038/373699a0openalex-snapshot

Scatter factor/hepatocyte growth factor is essential for liver development

inferredcites →https://doi.org/10.1038/nrm1261openalex-snapshot

Met, metastasis, motility and more

inferredcites →https://doi.org/10.1038/sj.ki.5000054openalex-snapshot

Renal fibrosis: New insights into the pathogenesis and therapeutics

inferredcites →https://doi.org/10.1038/sj.onc.1202547openalex-snapshot

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

inferredcites →https://doi.org/10.1038/sj.onc.1202899openalex-snapshot

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

inferredcites →https://doi.org/10.1038/sj.onc.1203859openalex-snapshot

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

inferredcites →https://doi.org/10.1038/sj.onc.1207691openalex-snapshot

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

inferredcites →https://doi.org/10.1038/sj.onc.1209088openalex-snapshot

The Akt/PKB pathway: molecular target for cancer drug discovery

inferredcites →https://doi.org/10.1038/sj.onc.1210201openalex-snapshot

From Tpr-Met to Met, tumorigenesis and tubes

inferredcites →https://doi.org/10.1038/sj.onc.1210697openalex-snapshot

Silencing the MET oncogene leads to regression of experimental tumors and metastases

inferredcites →https://doi.org/10.1042/bj3260763openalex-snapshot

Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli

inferredcites →https://doi.org/10.1046/j.1523-1755.2001.00717.xopenalex-snapshot

Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases

inferredcites →https://doi.org/10.1073/pnas.0306068101openalex-snapshot

Hepatocyte growth factor/ c-met signaling pathway is required for efficient liver regeneration and repair

inferredcites →https://doi.org/10.1073/pnas.0403412101openalex-snapshot

Met provides essential signals for liver regeneration

inferredcites →https://doi.org/10.1073/pnas.0508156103openalex-snapshot

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

inferredcites →https://doi.org/10.1073/pnas.0508776103openalex-snapshot

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

inferredcites →https://doi.org/10.1073/pnas.0700184104openalex-snapshot

Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist

inferredcites →https://doi.org/10.1073/pnas.89.23.11574openalex-snapshot

A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.

inferredcites →https://doi.org/10.1073/pnas.95.24.14379openalex-snapshot

Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth

inferredcites →https://doi.org/10.1074/jbc.270.28.16871openalex-snapshot

Sulfated Oligosaccharides Promote Hepatocyte Growth Factor Association and Govern Its Mitogenic Activity

inferredcites →https://doi.org/10.1074/jbc.272.14.9457openalex-snapshot

Heparin Binding and Oligomerization of Hepatocyte Growth Factor/Scatter Factor Isoforms

inferredcites →https://doi.org/10.1074/jbc.m105486200openalex-snapshot

Dissociation of Heparan Sulfate and Receptor Binding Domains of Hepatocyte Growth Factor Reveals That Heparan Sulfate-c-Met Interaction Facilitates Signaling

inferredcites →https://doi.org/10.1074/jbc.m408510200openalex-snapshot

The Interactions of Hepatocyte Growth Factor/Scatter Factor and Its NK1 and NK2 Variants with Glycosaminoglycans Using a Modified Gel Mobility Shift Assay

inferredcites →https://doi.org/10.1083/jcb.121.1.145openalex-snapshot

The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.

inferredcites →https://doi.org/10.1083/jcb.133.3.709openalex-snapshot

Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.

inferredcites →https://doi.org/10.1096/fasebj.14.2.399openalex-snapshot

Different point mutations in the met oncogene elicit distinct biological properties

inferredcites →https://doi.org/10.1097/pai.0b013e3181816ae2openalex-snapshot

A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings

inferredcites →https://doi.org/10.1111/j.1349-7006.2009.01343.xopenalex-snapshot

E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

inferredcites →https://doi.org/10.1126/science.1141478openalex-snapshot

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

inferredcites →https://doi.org/10.1126/science.1720571openalex-snapshot

Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript

inferredcites →https://doi.org/10.1126/science.1846706openalex-snapshot

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

inferredcites →https://doi.org/10.1158/0008-5472.can-04-2650openalex-snapshot

Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/0008-5472.can-05-2749openalex-snapshot

Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer

inferredcites →https://doi.org/10.1158/0008-5472.can-05-3329openalex-snapshot

Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met–Dependent Human Tumors

inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1418openalex-snapshot

A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo

inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1793openalex-snapshot

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.

inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-0071openalex-snapshot

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1306openalex-snapshot

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-0189openalex-snapshot

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-a100openalex-snapshot

Abstract A100: A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-a11openalex-snapshot

Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-a36openalex-snapshot

Abstract A36: Plasma biomarkers predicting outcome in patients with advanced RCC: Results from the sorafenib phase III TARGET trial

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-b210openalex-snapshot

Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-b269openalex-snapshot

Abstract B269: Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-c173openalex-snapshot

Abstract C173: Anti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody, in non-small cell lung cancer models

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-c181openalex-snapshot

Abstract C181: Preclinical efficacy and pharmacodynamics of SCH 900105 (AV-299) an anti-HGF antibody in an intracranial glioblastoma model

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-c212openalex-snapshot

Abstract C212: Pharmacological and pharmacokinetc characterization of RP1040, a novel and potent c-Met tyrosine kinase inhibitor

inferredcites →https://doi.org/10.1172/jci200422235openalex-snapshot

An uncleavable form of pro–scatter factor suppresses tumor growth and dissemination in mice

inferredcites →https://doi.org/10.1186/1471-2407-9-142openalex-snapshot

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

inferredcites →https://doi.org/10.1200/jco.2006.24.18_suppl.3041openalex-snapshot

A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs)

inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.14031openalex-snapshot

A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.15601openalex-snapshot

A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC)

inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.3526openalex-snapshot

Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors

inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.3551openalex-snapshot

Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors

inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.14657openalex-snapshot

First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors

inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.3522openalex-snapshot

A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)

inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.4572openalex-snapshot

Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study

inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.5103openalex-snapshot

A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

inferredcites →https://doi.org/10.1200/jco.2009.22.6993openalex-snapshot

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.2047openalex-snapshot

A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.2048openalex-snapshot

Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.2049openalex-snapshot

Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.3509openalex-snapshot

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.3519openalex-snapshot

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PF-00337210, a highly selective VEGFR inhibitor

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.4502openalex-snapshot

Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.e13511openalex-snapshot

A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.e14516openalex-snapshot

Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265–102)

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.e14525openalex-snapshot

Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265–101)

inferredcites →https://doi.org/10.2174/1566523043346453openalex-snapshot

Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)

inferredcites →https://doi.org/10.2174/1566524043359674openalex-snapshot

Hereditary Papillary Renal Carcinoma Type I

inferredcites →https://doi.org/10.2174/156652407779940486openalex-snapshot

Tyrosine Kinase Mutations in Human Cancer

inferredcites →https://doi.org/10.3748/wjg.v11.i47.7444openalex-snapshot

Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice

inferredcites →https://doi.org/10.4161/cc.4.4.1590openalex-snapshot

A Mouse Model of Activating Met Mutations

inferredcites →https://doi.org/10.5281/zenodo.894803openalex-snapshot

Differential Effects Of Hepatocyte Growth Factor Isoforms On Epithelial And Endothelial Tubulogenesis

inferredcites →https://doi.org/10.7270/q2dv1qm3openalex-snapshot

BindingDB Entry 50022503: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4825221openalex-extracted

The Hepatocyte Growth Factor/Cmet Axis in Autoimmune Cardiac Inflammation and Beyond

inferred← citeshttps://doi.org/10.1002/0471266949.bmc214.pub2openalex-snapshot

US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy

inferred← citeshttps://doi.org/10.1002/2211-5463.12578openalex-snapshot

Regorafenib reverses HGF ‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma

inferred← citeshttps://doi.org/10.1002/cmdc.202500279openalex-snapshot

Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024)

inferred← citeshttps://doi.org/10.1002/gcc.21954openalex-snapshot

Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma

inferred← citeshttps://doi.org/10.1002/ijc.26116openalex-snapshot

Tangled fibroblasts in tumor‐stroma interactions

inferred← citeshttps://doi.org/10.1002/ijc.27632openalex-snapshot

Targeted therapy for triple‐negative breast cancer: Where are we?

inferred← citeshttps://doi.org/10.1002/jhet.2529openalex-snapshot

Synthesis and Antimicrobial Activity of 1,3,4‐Oxadiazole‐2(3H)‐thione and Azidomethanone Derivatives Based on Quinoline‐4‐carbohydrazide Derivatives

inferred← citeshttps://doi.org/10.1002/mc.22741openalex-snapshot

MiR‐182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene

inferred← citeshttps://doi.org/10.1002/ptr.5551openalex-snapshot

Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C‐Met

inferred← citeshttps://doi.org/10.1007/978-1-4614-8815-6_5openalex-snapshot

The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.1007/978-1-4614-9167-5_9openalex-snapshot

Hypoxia, Metastasis, and Antiangiogenic Therapies

inferred← citeshttps://doi.org/10.1007/978-1-4939-2047-1_17openalex-snapshot

Targeted Therapies for Prostate Cancer

inferred← citeshttps://doi.org/10.1007/978-1-61779-612-8_8openalex-snapshot

The Epigenetics of Brain Tumors

inferred← citeshttps://doi.org/10.1007/978-1-61779-615-9_11openalex-snapshot

Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma

inferred← citeshttps://doi.org/10.1007/978-3-030-30651-9_8openalex-snapshot

Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion

inferred← citeshttps://doi.org/10.1007/978-3-030-47682-3_12openalex-snapshot

Development of Molecularly Targeted Agents in Early Phase Clinical Trials

inferred← citeshttps://doi.org/10.1007/978-3-319-78762-6_3openalex-snapshot

c-MET in Head and Neck Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.1007/978-94-007-2558-4_7openalex-snapshot

Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells

inferred← citeshttps://doi.org/10.1007/978-94-007-4719-7_8openalex-snapshot

Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion

inferred← citeshttps://doi.org/10.1007/978-94-007-4927-6_3openalex-snapshot

ECIS as a Tool in the Study of Metastasis Suppressor Genes: Epithelial Protein Lost In Neoplasm (EPLIN)

inferred← citeshttps://doi.org/10.1007/s00204-013-1035-3openalex-snapshot

Mechanisms of RAS/β-catenin interactions

inferred← citeshttps://doi.org/10.1007/s00280-013-2345-0openalex-snapshot

Vascular-targeted agents for the treatment of angiosarcoma

inferred← citeshttps://doi.org/10.1007/s10637-013-9934-yopenalex-snapshot

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

inferred← citeshttps://doi.org/10.1007/s11011-013-9401-7openalex-snapshot

Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma

inferred← citeshttps://doi.org/10.1007/s11515-014-1300-8openalex-snapshot

Priming cancer cells for drug resistance: role of the fibroblast niche

inferred← citeshttps://doi.org/10.1007/s11864-012-0222-4openalex-snapshot

Novel Therapies for the Treatment of Advanced Prostate Cancer

inferred← citeshttps://doi.org/10.1007/s11912-018-0684-zopenalex-snapshot

Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma

inferred← citeshttps://doi.org/10.1007/s12094-011-0719-5openalex-snapshot

MET and VEGF: synergistic targets in castration-resistant prostate cancer

inferred← citeshttps://doi.org/10.1007/s12291-017-0713-yopenalex-snapshot

Renal Cell Carcinoma: Molecular Aspects

inferred← citeshttps://doi.org/10.1007/s13277-014-2917-6openalex-snapshot

MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met

inferred← citeshttps://doi.org/10.1007/s13311-011-0029-1openalex-snapshot

Targeting Microvasculature for Neuroprotection after SCI

inferred← citeshttps://doi.org/10.1007/s13346-024-01564-3openalex-snapshot

Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies

inferred← citeshttps://doi.org/10.1016/b978-0-12-385859-7.00003-3openalex-snapshot

Metastasis Suppressor Genes

inferred← citeshttps://doi.org/10.1016/j.acthis.2011.07.010openalex-snapshot

Co-expression of hepatocyte growth factor and c-met in epithelial odontogenic tumors

inferred← citeshttps://doi.org/10.1016/j.bbrc.2012.12.120openalex-snapshot

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells

inferred← citeshttps://doi.org/10.1016/j.biocel.2012.06.027openalex-snapshot

MiR-410 regulates MET to influence the proliferation and invasion of glioma

inferred← citeshttps://doi.org/10.1016/j.bmc.2014.01.014openalex-snapshot

Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.bmc.2014.12.002openalex-snapshot

Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold

inferred← citeshttps://doi.org/10.1016/j.bmc.2016.03.061openalex-snapshot

Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2

inferred← citeshttps://doi.org/10.1016/j.bmc.2017.04.003openalex-snapshot

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

inferred← citeshttps://doi.org/10.1016/j.bmcl.2015.05.082openalex-snapshot

Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461

inferred← citeshttps://doi.org/10.1016/j.bmcl.2016.02.037openalex-snapshot

Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety

inferred← citeshttps://doi.org/10.1016/j.bmcl.2016.02.059openalex-snapshot

Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.bmcl.2017.12.063openalex-snapshot

Discovery of novel 2-substituted-4-phenoxypyridine derivatives as potential antitumor agents

inferred← citeshttps://doi.org/10.1016/j.ccr.2012.06.029openalex-snapshot

Targeted Disruption of Heparan Sulfate Interaction with Hepatocyte and Vascular Endothelial Growth Factors Blocks Normal and Oncogenic Signaling

inferred← citeshttps://doi.org/10.1016/j.cdtm.2017.06.002openalex-snapshot

Targeting MET in cancer therapy

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2019.09.005openalex-snapshot

Targeted treatment approaches in refractory germ cell tumors

inferred← citeshttps://doi.org/10.1016/j.ejca.2014.05.007openalex-snapshot

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients

inferred← citeshttps://doi.org/10.1016/j.ejmech.2013.08.019openalex-snapshot

Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

inferred← citeshttps://doi.org/10.1016/j.ejmech.2014.06.068openalex-snapshot

Design, synthesis and structure–activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents

inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.03.045openalex-snapshot

Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.08.044openalex-snapshot

Recent advances in the discovery of small molecule c-Met Kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.10.027openalex-snapshot

Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.11.034openalex-snapshot

Synthesis and antiproliferative activity of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety

inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.117177openalex-snapshot

Advances in the selective c-MET kinase inhibitors: Application of fused [5,6]-Bicyclic nitrogen-containing cores for anticancer drug design

inferred← citeshttps://doi.org/10.1016/j.ejphar.2017.03.032openalex-snapshot

Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration

inferred← citeshttps://doi.org/10.1016/j.febslet.2011.05.042openalex-snapshot

miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway

inferred← citeshttps://doi.org/10.1016/j.gene.2012.12.083openalex-snapshot

Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: Identification of mRNAs and microRNAs involved in tumor invasion

inferred← citeshttps://doi.org/10.1016/j.jtocrr.2022.100449openalex-snapshot

Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors

inferred← citeshttps://doi.org/10.1016/j.jvir.2013.02.015openalex-snapshot

Image-guided Thermal Ablation of Tumors Increases the Plasma Level of Interleukin-6 and Interleukin-10

inferred← citeshttps://doi.org/10.1016/j.lfs.2021.119270openalex-snapshot

Understanding stem cells and its pivotal role in regenerative medicine

inferred← citeshttps://doi.org/10.1016/j.stemcr.2013.06.006openalex-snapshot

Multipotent Human Mesenchymal Stromal Cells Mediate Expansion of Myeloid-Derived Suppressor Cells via Hepatocyte Growth Factor/c-Met and STAT3

inferred← citeshttps://doi.org/10.1016/j.trac.2024.117681openalex-snapshot

Current smartphone-assisted point-of-care cancer detection: Towards supporting personalized cancer monitoring

inferred← citeshttps://doi.org/10.1016/j.ucl.2012.07.008openalex-snapshot

Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer

inferred← citeshttps://doi.org/10.1021/acs.nanolett.8b01879openalex-snapshot

Peptide-Functionalized Nanoinhibitor Restrains Brain Tumor Growth by Abrogating Mesenchymal-Epithelial Transition Factor (MET) Signaling

inferred← citeshttps://doi.org/10.1021/acschembio.5c00675openalex-snapshot

Chemical Screening of RIKEN Natural Products Depository Identified a MYCN Expression Inhibitor Partially through HGF–MET Signaling Pathway

inferred← citeshttps://doi.org/10.1038/aja.2010.26openalex-snapshot

Comment on “Effect of transferred NK4 gene on proliferation, migration, invasion, and apoptosis of human prostate cancer DU145 cells” by Dan Yue et al. in Asian Journal of Andrology

inferred← citeshttps://doi.org/10.1038/aps.2010.106openalex-snapshot

Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy

inferred← citeshttps://doi.org/10.1038/bjc.2012.237openalex-snapshot

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

inferred← citeshttps://doi.org/10.1038/nm.2753openalex-snapshot

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

inferred← citeshttps://doi.org/10.1038/onc.2011.260openalex-snapshot

miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222

inferred← citeshttps://doi.org/10.1038/onc.2012.233openalex-snapshot

PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity

inferred← citeshttps://doi.org/10.1038/onc.2017.272openalex-snapshot

Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis

inferred← citeshttps://doi.org/10.1038/s41392-022-01297-0openalex-snapshot

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

inferred← citeshttps://doi.org/10.1038/s41598-021-81898-xopenalex-snapshot

Growth factor dependent changes in nanoscale architecture of focal adhesions

inferred← citeshttps://doi.org/10.1038/s41598-025-17102-1openalex-snapshot

Single-cell transcriptome sequencing reveals tumor stem cells and their molecular characteristics in intrahepatic cholangiocarcinoma

inferred← citeshttps://doi.org/10.1038/srep11749openalex-snapshot

INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models

inferred← citeshttps://doi.org/10.1039/c1ob06186kopenalex-snapshot

Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay

inferred← citeshttps://doi.org/10.1039/c2an35464kopenalex-snapshot

Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates

inferred← citeshttps://doi.org/10.1039/c3mb70288jopenalex-snapshot

Functional and pathway enrichment analysis for integrated regulatory network of high- and low-metastatic lung cancer

inferred← citeshttps://doi.org/10.1039/c9cs00473dopenalex-snapshot

Nongenetic engineering strategies for regulating receptor oligomerization in living cells

inferred← citeshttps://doi.org/10.1039/d6cc03360aopenalex-snapshot

A potassium-triggered bimolecular G-quadruplex DNA nanomachine activates Met signaling to promote cell migration

inferred← citeshttps://doi.org/10.1073/pnas.0914295107openalex-snapshot

Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion

inferred← citeshttps://doi.org/10.1080/13543776.2019.1552261openalex-snapshot

c-Met kinase inhibitors: an update patent review (2014-2017)

inferred← citeshttps://doi.org/10.1080/13543784.2020.1699532openalex-snapshot

MET inhibitors in cancer: pitfalls and challenges

inferred← citeshttps://doi.org/10.1080/13543784.2025.2606118openalex-snapshot

Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years?

inferred← citeshttps://doi.org/10.1093/annonc/mdt014openalex-snapshot

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors

inferred← citeshttps://doi.org/10.1097/hjh.0000000000001808openalex-snapshot

Transactivation of Met signalling by semaphorin4D in human placenta

inferred← citeshttps://doi.org/10.1097/md.0000000000034931openalex-snapshot

Analysis of genomic alterations in primary central nervous system lymphoma

inferred← citeshttps://doi.org/10.1101/gad.1973010openalex-snapshot

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

inferred← citeshttps://doi.org/10.1111/cas.12104openalex-snapshot

Prostate cancer stem‐like cells/cancer‐initiating cells have an autocrine system of hepatocyte growth factor

inferred← citeshttps://doi.org/10.1111/cas.12387openalex-snapshot

Saracatinib impairs the peritoneal dissemination of diffuse‐type gastric carcinoma cells resistant to M et and fibroblast growth factor receptor inhibitors

inferred← citeshttps://doi.org/10.1111/cas.12891openalex-snapshot

Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells

inferred← citeshttps://doi.org/10.1111/cas.14180openalex-snapshot

SHR ‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD 9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met

inferred← citeshttps://doi.org/10.1111/cbdd.13192openalex-snapshot

Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3‐triazole moiety as c‐Met kinase inhibitors

inferred← citeshttps://doi.org/10.1124/mol.112.084111openalex-snapshot

A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines

inferred← citeshttps://doi.org/10.1152/ajprenal.00196.2022openalex-snapshot

The injury-induced transcription factor SOX9 alters the expression of LBR, HMGA2, and HIPK3 in the human kidney

inferred← citeshttps://doi.org/10.1155/2011/483154openalex-snapshot

Liposarcoma: Molecular Genetics and Therapeutics

inferred← citeshttps://doi.org/10.1155/2014/764981openalex-snapshot

Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways

inferred← citeshttps://doi.org/10.1155/2015/192406openalex-snapshot

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors

inferred← citeshttps://doi.org/10.1155/2015/795738openalex-snapshot

The Genetic and Environmental Factors for Keratoconus

inferred← citeshttps://doi.org/10.1158/0008-5472.can-10-2527openalex-snapshot

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.c.6519236openalex-snapshot

Data from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.c.6519236.v1openalex-snapshot

Data from IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-10-3314openalex-snapshot

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-11-0244openalex-snapshot

Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-11-2830openalex-snapshot

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-12-2832openalex-snapshot

Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-13-0423openalex-snapshot

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-14-1661openalex-snapshot

Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-16-1568openalex-snapshot

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

inferred← citeshttps://doi.org/10.1158/1535-7163.mct-12-1011openalex-snapshot

A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities

inferred← citeshttps://doi.org/10.1158/1535-7163.mct-13-0109openalex-snapshot

Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1158/1535-7163.mct-13-0187openalex-snapshot

Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells

inferred← citeshttps://doi.org/10.1158/1541-7786.mcr-15-0022openalex-snapshot

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition–Associated Checkpoint Abrogation

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-11-0220openalex-snapshot

Curing “Incurable” Cancer

inferred← citeshttps://doi.org/10.1159/000366337openalex-snapshot

MicroRNA-409-3p Functions as a Tumor Suppressor in Human Lung Adenocarcinoma by Targeting c-Met

inferred← citeshttps://doi.org/10.1172/jci65566openalex-snapshot

HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma

inferred← citeshttps://doi.org/10.1177/1010428317699118openalex-snapshot

The c-Met receptor: Implication for targeted therapies in colorectal cancer

inferred← citeshttps://doi.org/10.1177/1758834011423402openalex-snapshot

c-MET: an exciting new target for anticancer therapy

inferred← citeshttps://doi.org/10.1177/1758834011423540openalex-snapshot

Future directions in the evaluation of c-MET-driven malignancies

inferred← citeshttps://doi.org/10.1186/1471-2407-12-198openalex-snapshot

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607

inferred← citeshttps://doi.org/10.1186/1476-4598-11-64openalex-snapshot

Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis

inferred← citeshttps://doi.org/10.1186/1479-5876-12-199openalex-snapshot

Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder

inferred← citeshttps://doi.org/10.1186/1746-1596-8-16openalex-snapshot

High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma

inferred← citeshttps://doi.org/10.1186/bcr2617openalex-snapshot

The Met oncogene and basal-like breast cancer: another culprit to watch out for?

inferred← citeshttps://doi.org/10.1186/s12885-015-1662-6openalex-snapshot

c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence

inferred← citeshttps://doi.org/10.1186/s12935-024-03455-6openalex-snapshot

AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers

inferred← citeshttps://doi.org/10.1186/s12943-018-0796-yopenalex-snapshot

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

inferred← citeshttps://doi.org/10.1186/s13046-019-1104-4openalex-snapshot

A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth

inferred← citeshttps://doi.org/10.1186/s13058-015-0547-6openalex-snapshot

The clinical and functional significance of c-Met in breast cancer: a review

inferred← citeshttps://doi.org/10.1200/jco.2011.35.5677openalex-snapshot

Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma

inferred← citeshttps://doi.org/10.1200/jco.2011.40.3774openalex-snapshot

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

inferred← citeshttps://doi.org/10.1200/jco.2012.46.4289openalex-snapshot

Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma

inferred← citeshttps://doi.org/10.1371/journal.pone.0053974openalex-snapshot

HGF and c-Met Interaction Promotes Migration in Human Chondrosarcoma Cells

inferred← citeshttps://doi.org/10.1371/journal.pone.0073312openalex-snapshot

Hepatic Stellate Cells Secreted Hepatocyte Growth Factor Contributes to the Chemoresistance of Hepatocellular Carcinoma

inferred← citeshttps://doi.org/10.1371/journal.pone.0148075openalex-snapshot

Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells

inferred← citeshttps://doi.org/10.14429/dlsj.1.10059openalex-snapshot

Role of Growth Factor Signaling in Cancer

inferred← citeshttps://doi.org/10.14753/se.2014.1924openalex-snapshot

ONCOGENE DEPENDENT REGULATION OF MIGRATION AND PROLIFERATION IN HUMAN TUMOR CELLS

inferred← citeshttps://doi.org/10.14800/ccm.1237openalex-snapshot

Mechanisms of miRNA expression in regulating glioma invasion

inferred← citeshttps://doi.org/10.1517/14728222.2012.677441openalex-snapshot

Novel molecular targets for the therapy of urothelial carcinoma

inferred← citeshttps://doi.org/10.1517/14728222.2014.938050openalex-snapshot

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

inferred← citeshttps://doi.org/10.1517/14728222.2016.1162293openalex-snapshot

Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair

inferred← citeshttps://doi.org/10.1586/14737159.2015.1046436openalex-snapshot

MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?

inferred← citeshttps://doi.org/10.1586/era.11.94openalex-snapshot

The Wnt signaling pathway: implications for therapy in osteosarcoma

inferred← citeshttps://doi.org/10.1684/bdc.2011.1472openalex-snapshot

Les inhibiteurs de tyrosine kinase

inferred← citeshttps://doi.org/10.18632/oncotarget.16173openalex-snapshot

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.22379openalex-snapshot

Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions

inferred← citeshttps://doi.org/10.18632/oncotarget.23474openalex-snapshot

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.8215openalex-snapshot

Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology

inferred← citeshttps://doi.org/10.21037/jgo-21-536openalex-snapshot

Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer

inferred← citeshttps://doi.org/10.21037/tlcr.2019.10.19openalex-snapshot

Genetic alteration profile of EGFR-mutant resected IIB–IIIA stage NSCLC and correlation to clinical outcomes

inferred← citeshttps://doi.org/10.2147/dddt.s224491openalex-snapshot

Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma

inferred← citeshttps://doi.org/10.2147/lctt.s35168openalex-snapshot

MET overexpression and gene amplification in NSCLC: a clinical perspective

inferred← citeshttps://doi.org/10.2147/ott.s148604openalex-snapshot

Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents

inferred← citeshttps://doi.org/10.2174/0115680096285034240323035013openalex-snapshot

The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells

inferred← citeshttps://doi.org/10.2174/1568026619666190712205353openalex-snapshot

Recent Progress in the Development of Small Molecule c-Met Inhibitors

inferred← citeshttps://doi.org/10.2174/9789815080292123010010openalex-snapshot

Chromosome 7

inferred← citeshttps://doi.org/10.2217/crc.12.40openalex-snapshot

Role of the MET–HGF axis in colorectal cancer: precepts and prospects

inferred← citeshttps://doi.org/10.2217/fon-2019-0653openalex-snapshot

Dose-Escalation Trial of the ALK, MET & ROS1 Inhibitor, Crizotinib, in Patients with Advanced Cancer

inferred← citeshttps://doi.org/10.2310/jim.0b013e31821451a1openalex-snapshot

Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer

inferred← citeshttps://doi.org/10.2967/jnumed.116.187310openalex-snapshot

89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection

inferred← citeshttps://doi.org/10.2991/iwmecs-15.2015.46openalex-snapshot

Synthesis of tert-butyl 4-((2-methoxy-4-(methoxycarbonyl) phenoxy) methyl) piperidine-1-carboxylate

inferred← citeshttps://doi.org/10.3109/1354750x.2012.670865openalex-snapshot

Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474

inferred← citeshttps://doi.org/10.3384/diss.diva-135047openalex-snapshot

The receptor tyrosine kinase Met and the protein tyrosine phosphatase PTPN2 in breast cancer

inferred← citeshttps://doi.org/10.3389/fonc.2020.01642openalex-snapshot

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

inferred← citeshttps://doi.org/10.3390/biomedicines3010071openalex-snapshot

HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation

inferred← citeshttps://doi.org/10.3390/cancers13143459openalex-snapshot

Tumor Extracellular Vesicles Regulate Macrophage-Driven Metastasis through CCL5

inferred← citeshttps://doi.org/10.3390/cancers15143561openalex-snapshot

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review

inferred← citeshttps://doi.org/10.3390/ijms232314884openalex-snapshot

Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in Multidrug-Resistant Human Uterine Sarcoma Cells

inferred← citeshttps://doi.org/10.3390/ph4040567openalex-snapshot

Molecular Approaches To Target GPCRs in Cancer Therapy

inferred← citeshttps://doi.org/10.3390/toxins5020336openalex-snapshot

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation

inferred← citeshttps://doi.org/10.3760/cma.j.issn.0366-6999.20131889openalex-snapshot

Expression of hepatocyte growth factor and its receptor c-Met in lensinduced myopia in guinea pigs

inferred← citeshttps://doi.org/10.3892/ijo.2024.5655openalex-snapshot

Investigating the molecular mechanisms of microRNA‑409‑3p in tumor progression: Towards targeted therapeutics (Review)

inferred← citeshttps://doi.org/10.3892/mmr.2014.2293openalex-snapshot

Expression of growth-regulated oncogene-1, hepatocyte growth factor, platelet-derived growth factor-AA and soluble E-selectin and their association with high-risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix

inferred← citeshttps://doi.org/10.3892/mmr.2015.3865openalex-snapshot

Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signaling pathway

inferred← citeshttps://doi.org/10.3892/ol.2014.2390openalex-snapshot

Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo

inferred← citeshttps://doi.org/10.3892/ol.2015.3964openalex-snapshot

Expression of hepatocyte growth factor and c-Met is characteristic of α-fetoprotein-producing colorectal adenocarcinoma: A report of three cases

inferred← citeshttps://doi.org/10.3892/ol.2025.15106openalex-snapshot

Application of serum anti‑ENO1 and anti‑SSNA1 antibody biomarkers in predicting the prognosis of gastric cancer

inferred← citeshttps://doi.org/10.3892/or.2017.6073openalex-snapshot

Role of c-Met in the progression of human oral squamous cell carcinoma and its potential as a therapeutic target

inferred← citeshttps://doi.org/10.3892/or.2018.6590openalex-snapshot

CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma

inferred← citeshttps://doi.org/10.3978/j.issn.2218-6751.2012.09.04openalex-snapshot

Role of HGF/MET axis in resistance of lung cancer to contemporary management.

inferred← citeshttps://doi.org/10.3978/j.issn.2218-6751.2012.12.04openalex-snapshot

MET inhibition in lung cancer.

inferred← citeshttps://doi.org/10.3980/j.issn.2222-3959.2014.02.09openalex-snapshot

Effects of hepatocyte growth factor on MMP-2 expression in scleral fibroblasts from a guinea pig myopia model.

inferred← citeshttps://doi.org/10.4068/cmj.2015.51.2.81openalex-snapshot

Clinical Significance ofMETGene Copy Number in Patients with Curatively Resected Gastric Cancer

inferred← citeshttps://doi.org/10.4149/neo_2017_308openalex-snapshot

PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma

inferred← citeshttps://doi.org/10.4172/2161-0681.1000315openalex-snapshot

Correlation among Genetic Variations of c-MET in Chinese Patient with Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.5493/wjem.v2.i2.7openalex-snapshot

Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies

inferred← citeshttps://doi.org/10.5772/22241openalex-snapshot

Significance, Mechanisms, and Progress of Anticancer Drugs Targeting HGF-Met

inferred← citeshttps://doi.org/10.5772/26485openalex-snapshot

Endocrine Delivery System of NK4, an HGF-Antagonist and Anti-Angiogenic Regulator, for Inhibitions of Tumor Growth, Invasion and Metastasis

inferred← citeshttps://doi.org/10.6084/m9.figshare.26549309openalex-snapshot

Additional file 1 of AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers

inferred← citeshttps://doi.org/10.6084/m9.figshare.26549434openalex-snapshot

Additional file 2 of AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers

inferred← citeshttps://doi.org/10.6084/m9.figshare.26759489openalex-snapshot

Additional file 3 of AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers

inferred← citeshttps://doi.org/10.7150/ijms.7769openalex-snapshot

Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation

inferred← citeshttps://doi.org/10.7150/jca.14604openalex-snapshot

MET Inhibition in Clear Cell Renal Cell Carcinoma

inferred← citeshttps://doi.org/10.7759/cureus.59384openalex-snapshot

An Interesting Case of Alpha-Fetoprotein (AFP)-Producing Pancreaticoduodenal Tumor

inferred← citeshttps://doi.org/10.7916/d8931130openalex-snapshot

Studies on mammalian pre-mRNA splicing : connections to transcription and cancer

inferred← citeshttps://doi.org/10.82444/warw.33758431openalex-snapshot

Alternative Splicing (AS) and Epithelial-to-Mesenchymal Transition (EMT) programming in cellular model of breast cancer

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.